Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06238453
Other study ID # B.30.2.ATA.0.01.00/681
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 12, 2024
Est. completion date August 10, 2024

Study information

Verified date February 2024
Source Mus Alparlan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

It is known that the healing process of breast cancer is accelerated thanks to the early diagnosis and effective treatment. Mammography screening is an important diagnostic method in the early diagnosis of breast cancer. It is thought that the education to be given according to the Health Belief Model will make important contributions to developing a positive attitude in breast cancer screenings and regular mammography.


Description:

The research will consist of women who have previously applied to Erzurum Cancer Early Diagnosis, Screening and Education Center, had mammography taken, and whose phone records are available, whose appointment has been made since December 2022, and who meet the screening selection criteria. Women who have had a mammography appointment from KETEM and have not taken it yet, request their phone information. After the women were searched one by one to identify those who fit their characteristics and volunteers, they would leave the simple random experiment control elements. During the searches, all women will be invited to KETEM to have a mammogram again. The experimental group will send educational content through the WhatsApp application once a week, and will also answer questions and provide individual counseling. A total of 8 weeks of intervention will be implemented, the first 6 weeks of training will be provided with training presentations and the last 2 weeks of training video will be sent. Feedback will be received after the training presentations are followed through the WhatsApp application where they are read. The control group will not take any action and will be invited to KETEM for mammography. Pre-test and post-analysis phone access will be collected. At the end of the training, he will have the final examinations applied after 3 months. The number of women who participated in the study will be determined by examining the KETEM records of mammography.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 134
Est. completion date August 10, 2024
Est. primary completion date April 2, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 69 Years
Eligibility Inclusion Criteria: - Be between the ages of 40-69, - Be woman, - Not having been diagnosed with breast cancer, - Not to be pregnant, lactating or puerperal, - Absence of a mental illness - At least 2 years have passed since the last mammogram, - Being able to use the WhatsApp application Exclusion Criteria: - Having had problems with breast cancer before, - Having a mammogram at regular intervals, - Having had breast-conserving surgery for any purpose.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Kemal Yaran

Outcome

Type Measure Description Time frame Safety issue
Primary Pre-test evaluation The Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to all women in the experimental and control groups for pre-test purposes. There is no overall total score of the Health Belief Model Scale on Breast Cancer Screenings. Each sub-dimension's own total score is evaluated. The scale is a Likert type scale scored from 1 to 5. The scoring of the scale ranges from 1 point for "strongly disagree" to 5 points for "strongly agree". Increasing scores obtained from sub-dimensions indicate that the perception of that sub-dimension is high. Mammography Self-Efficacy Scale has ten items and five-point Likert type. The scale answers "strongly disagree" are evaluated as 1 point, "disagree" as 2 points, "undecided" as 3 points, "agree" as 4 points and "strongly agree" as 5 points. A higher score for each dimension indicates a higher probability of having a mammogram. Three month
Primary Posttest evaluation Training presentations will be sent to the experimental group in the first 6 weeks and training videos will be sent in the last 2 weeks. A total of 8 weeks of intervention will be implemented. Training content will be sent via WhatsApp application once a week. No intervention will be made to the control group by the researchers during this period. Those in the control group will be invited to KETEM to have a mammogram. Three months after the training is completed, the Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to both groups for posttest purposes. Six month
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A